## Joel Corcoran

Phone (H): (833) 753-1851 DOB: 11/30/1980 Gender: Male Age: 44 Patient ID: 53573860 STATUS: Final

Time Reported: 01/21/2025 08:57 PM

UTC

Quest

**Received:** 01/21/2025 09:04 PM

UTC

Accession SZ687587R

Number:

Source:

**Lab Ref #:** 915188

ORDERING PHYSICIAN:

## Joshua A Emdur,

D.O.

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test	In Range	Out Of Range	Reference Range	Lab

FASTING: YES

FASTING: YES

IRON, TIBC AND FERRITIN PANEL	Collected: 01/13/2025 05:55 PM UTC	Received: 01	/13/2025 05:56 PM U	TC
IRON, TOTAL	141		50-180 mcg/dL	UL
IRON BINDING CAPACITY	284		250-425 mcg/dL	UL
			(calc)	
% SATURATION		<u>50</u> H	20-48 % (calc)	UL
FERRITIN	182		38-380 ng/mL	UL
	· · · ·	/0005 05 50 <b>D</b> B		

### LIPOPROTEIN (a) Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC

LIPOPROTEIN (a) <10

nmol/L EN

6-22 (calc)

Verified by repeat analysis.

Reference Range <75

Risk:

Optimal <75 Moderate 75-125 High >125

Cardiovascular event risk category cut points (optimal, moderate, high) are based on Tsimika S. JACC 2017;69:692-711.

URIC ACID Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC

URIC ACID 5.5 4.0-8.0 mg/dL

Therapeutic target for gout patients: <6.0 mg/dL

# COMPREHENSIVE METABOLIC PANEL Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC UTC 95 65-99 mg/dL

Fasting reference interval

 UREA NITROGEN (BUN)
 15
 7-25 mg/dL UL

 CREATININE
 1.11
 0.60-1.29 mg/dL UL

 EGFR
 84
 > OR = 60 mL/min/1. UL

 73m2 73m2 

BUN/CREATININE RATIO SEE NOTE:
Not Reported: BUN and Creatinine are within

reference range.



Printed from Health Gorilla Secure Clinical Network. Copyright © 2025 Health Gorilla Inc. https://www.healthgorilla.com

The contents of this document and/or fax transmission are intended only for the use of the individual or entity to which they are addressed and may contain information that is legally privileged, confidential and exempt from disclosure, including protected health information. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this document is strictly prohibited. If you have received or obtained this document or fax transmission in error, please notify the original sender or contact Health Gorilla Inc. at 1-844-446-7455 immediately by telephone or by email at privacy@healthgorilla.com and delete this document immediately.

UL

UL

### Joel Corcoran

Phone (H): (833) 753-1851 DOB: 11/30/1980 Gender: Male Age: 44 Patient ID: 53573860 STATUS: Final

Source: Quest

Time Reported: 01/21/2025 08:57 PM

UTC

**Received:** 01/21/2025 09:04 PM

UTC

Accession SZ687587R

Number:

**Lab Ref #:** 915188

ORDERING PHYSICIAN:

Joshua A Emdur,

**D.O**.

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test	In Range	Out Of Range	Reference Range	Lab
SODIUM	138		135-146 mmol/L	UL
POTASSIUM	4.3		3.5-5.3 mmol/L	UL
CHLORIDE	104		98-110 mmol/L	UL
CARBON DIOXIDE	26		20-32 mmol/L	UL
CALCIUM	9.2		8.6-10.3 mg/dL	UL
PROTEIN, TOTAL	6.8		6.1-8.1 g/dL	UL
ALBUMIN	4.6		3.6-5.1 g/dL	UL
GLOBULIN	2.2		1.9-3.7 g/dL (calc)	UL
ALBUMIN/GLOBULIN RATIO	2.1		1.0-2.5 (calc)	UL
BILIRUBIN, TOTAL	1.1		0.2-1.2 mg/dL	UL
ALKALINE PHOSPHATASE	50		36-130 U/L	UL
AST	22		10-40 U/L	UL
ALT	29		9-46 U/L	UL

ALBUMIN, RANDOM URINE W/O CREATININE Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC

ALBUMIN, URINE 0.4 See Note: mg/dL UL

Reference Range:

Reference Range Not established

RAM

The ADA defines abnormalities in albumin excretion as follows:

Albuminuria Category Result (mg/g creatinine)

Normal to Mildly increased <30 Moderately increased 30-299 Severely increased > OR = 300

The ADA recommends that at least two of three specimens collected within a 3-6 month period be abnormal before considering a patient to be within a diagnostic category.

URINALYSIS, COMPLETE	Collected: 01/13/2025 05:55 PM UTC	Received: 01/13/2025 05:56 PM UTC	
COLOR	YELLOW	YELLOW	UL
APPEARANCE	CLEAR	CLEAR	UL
SPECIFIC GRAVITY	1.013	1.001-1.035	UL
PH	6.0	5.0-8.0	UL
GLUCOSE	NEGATIVE	NEGATIVE	UL
BILIRUBIN	NEGATIVE	NEGATIVE	UL
KETONES	NEGATIVE	NEGATIVE	UL
OCCULT BLOOD	NEGATIVE	NEGATIVE	UL



Printed from Health Gorilla Secure Clinical Network. Copyright © 2025 Health Gorilla Inc. https://www.healthgorilla.com

## Joel Corcoran

Phone (H): (833) 753-1851 DOB: 11/30/1980 Gender: Male Age: 44 Patient ID: 53573860 STATUS: Final

Source: Quest

Time Reported: 01/21/2025 08:57 PM

UTC

**Received:** 01/21/2025 09:04 PM

UTC

Accession SZ687587R

Number:

**Lab Ref #:** 915188

ORDERING PHYSICIAN:

## Joshua A Emdur,

**D.O.** 600 Congress Avenue

Floor 14 Austin, TX, 78701

Test	In Range	Out Of Range	Reference Range	Lab
PROTEIN	NEGATIVE		NEGATIVE	UL
NITRITE	NEGATIVE		NEGATIVE	UL
LEUKOCYTE ESTERASE	NEGATIVE		NEGATIVE	UL
WBC	NONE SEEN		< OR = 5 /HPF	UL
RBC	NONE SEEN		< OR = 2 /HPF	UL
SQUAMOUS EPITHELIAL CELLS	NONE SEEN		< OR = 5 /HPF	UL
BACTERIA	NONE SEEN		NONE SEEN /HPF	UL
HYALINE CAST	NONE SEEN		NONE SEEN /LPF	UL
NOTE				UL

This urine was analyzed for the presence of WBC, RBC, bacteria, casts, and other formed elements.

Only those elements seen were reported.

		Received: 01/13/2025 05:56 PM UTC	
WHITE BLOOD CELL COUNT	5.2	3.8-10.8 Thousand	UL
		/uL	
RED BLOOD CELL COUNT	5.01	4.20-5.80 Million/uL	UL
HEMOGLOBIN	16.1	13.2-17.1 g/dL	UL
HEMATOCRIT	47.8	38.5-50.0 %	UL
MCV	95.4	80.0-100.0 fL	UL
MCH	32.1	27.0-33.0 pg	UL
MCHC	33.7	32.0-36.0 g/dL	UL
For adults, a sli	ght decrease in the calculated	· · · · · · · · · · · · · · · · · · ·	
value (in the ran	age of 30 to 32 $\mathrm{g/dL})$ is most 1	likely	
not clinically si	gnificant; however, it should	be	
interpreted with	caution in correlation with ot	ther	
red cell paramete	ers and the patient's clinical		
condition.			
RDW	11.9	11.0-15.0 %	UL
PLATELET COUNT	232	140-400 Thousand	UL
		/uL	
MPV	10.1	7.5-12.5 fL	UL
ABSOLUTE NEUTROPHILS	2808	1500-7800 cells/uL	UL
ABSOLUTE LYMPHOCYTES	1695	850-3900 cells/uL	UL
ABSOLUTE MONOCYTES	582	200-950 cells/uL	UL
ABSOLUTE EOSINOPHILS	62	15-500 cells/uL	UL
ABSOLUTE BASOPHILS	52	0-200 cells/uL	UL
NEUTROPHILS	54	%	UL
LYMPHOCYTES	32.6	%	UL
MONOCYTES	11.2	%	UL
EOSINOPHILS	1.2	%	UL
BASOPHILS	1.0	%	UL
	1.0	70	

HS CRP Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC



Printed from Health Gorilla Secure Clinical Network. Copyright © 2025 Health Gorilla Inc. https://www.healthgorilla.com

## Joel Corcoran

Phone (H): (833) 753-1851 DOB: 11/30/1980 Gender: Male Age: 44 Patient ID: 53573860 STATUS: Final

Source: Quest

Time Reported: 01/21/2025 08:57 PM

UTC

**Received:** 01/21/2025 09:04 PM

UTC

Accession SZ687587R

Number:

**Lab Ref #:** 915188

ORDERING PHYSICIAN:

## Joshua A Emdur,

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test	In Range	Out Of Range	Reference Range	Lab	
HS CRP	0.6		ma/L	UL	

Reference Range

Optimal <1.0

Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87.

For ages >17 Years:

hs-CRP mg/L

 Risk According to AHA/CDC Guidelines
 Lower relative cardiovascular risk.
 Average relative cardiovascular risk.
 Higher relative cardiovascular risk.
 Consider retesting in 1 to 2 weeks to exclude a benign transient elevation in the baseline CRP value secondary to infection or inflammation.
 Persistent elevation, upon retesting, may be associated with infection and

inflammation.

Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice:

A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107(3):

499-511.

#### CORTISOL, TOTAL, LC/MS Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC

CORTISOL, TOTAL, LC/MS

9.9

mcg/dL

ΕZ

Adult Reference Ranges for Cortisol, Total:

8-10 AM 4.6-20.6 mcg/dL 4-6 PM 1.8-13.6 mcg/dL

Cortisol Response to ACTH

Peak >20.0 mcg/dL

Peak >16.0 mcg/dL after IM injection

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

INSULIN Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC

INSULIN 5.8 uIU/mL EN



Printed from Health Gorilla Secure Clinical Network. Copyright © 2025 Health Gorilla Inc. https://www.healthgorilla.com

## Joel Corcoran

Phone (H): (833) 753-1851 11/30/1980 DOB: Gender: Male Age: 44 Patient ID: 53573860

STATUS: Final

Source: Quest

01/21/2025 08:57 PM **Time Reported:** 

UTC

01/21/2025 09:04 PM Received:

UTC

Accession SZ687587R

Number:

Lab Ref #: 915188 ORDERING PHYSICIAN:

## Joshua A Emdur,

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test		In Range	Out Of Range	Reference Range	Lab
	Reference Range	< or = 18.4			
	Risk:				

Optimal < or = 18.4

Moderate NA High >18.4

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Insulin Reference Interval studies performed at Quest Diagnostics in 2022.

<b>T4, FREE</b> Collected: 01/13/2	025 05:55 PM UTC Received: 01/13/2025 05:56 PM UT	0	
T4, FREE	1.3	0.8-1.8 ng/dL	UL
<b>TSH</b> Collected: 01/13/2025 0	5:55 PM UTC Received: 01/13/2025 05:56 PM UTC		
TSH	0.93	0.40-4.50 mIU/L	UL
<b>T3, FREE</b> Collected: 01/13/2	025 05:55 PM UTC Received: 01/13/2025 05:56 PM UT	C	
T3, FREE	3.9	2.3-4.2 pg/mL	UL
VITAMIN D.25-OH.TOTAL.IA	Collected: 01/13/2025 05:55 PM UTC Received: 01/13	/2025 05:56 PM UTC	

UL VITAMIN D,25-OH,TOTAL,IA 30-100 ng/mL 41

Vitamin D Status 25-OH Vitamin D:

Deficiency: <20 ng/mL Insufficiency:  $20 - 29 \, \text{ng/mL}$ Optimal: > or = 30 ng/mL

For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssureD(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs).

See Note 1

#### APOLIPOPROTEIN B Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC **APOLIPOPROTEIN B** <u>101</u> H mg/dL

Reference Range

Risk Category:

Optimal < 90 Moderate 90 - 119High > or = 120



Printed from Health Gorilla Secure Clinical Network. Copyright © 2025 Health Gorilla Inc. https://www.healthgorilla.com

The contents of this document and/or fax transmission are intended only for the use of the individual or entity to which they are addressed and may contain information that is legally privileged, confidential and exempt from disclosure, including protected health information. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this document is strictly prohibited. If you have received or obtained this document or fax transmission in error, please notify the original sender or contact Health Gorilla Inc. at 1-844-446-7455 immediately by telephone or by email at privacy@healthgorilla.com and delete this document immediately.

ΕN

## Joel Corcoran

Phone (H): (833) 753-1851 DOB: 11/30/1980 Gender: Male Age: 44 Patient ID: 53573860 STATUS: Final

Source: Quest

Time Reported: 01/21/2025 08:57 PM

UTC

**Received:** 01/21/2025 09:04 PM

UTC

Accession SZ687587R

Number:

**Lab Ref #:** 915188

ORDERING PHYSICIAN:

## Joshua A Emdur,

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test In Range Out Of Range Reference Range Lab

Cardiovascular event risk category cut points (optimal, moderate, high) are based on National Lipid Association recommendations-Jacobson TA et al. J of Clin Lipid. 2015; 9: 129-169 and Jellinger PS et al. Endocr Pract. 2017;23(Suppl 2):1-87.

#### HEMOGLOBIN A1c Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC

**HEMOGLOBIN A1c** 

5.3

<5.7 % of total Hgb

UL

For the purpose of screening for the presence of diabetes:

<5.7% Consistent with the absence of diabetes
5.7-6.4% Consistent with increased risk for diabetes</pre>

(prediabetes)

> or =6.5% Consistent with diabetes

This assay result is consistent with a decreased risk of diabetes.

Currently, no consensus exists regarding use of hemoglobin Alc for diagnosis of diabetes in children.

According to American Diabetes Association (ADA) guidelines, hemoglobin Alc <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA).

#### MERCURY, BLOOD Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC

MERCURY, BLOOD

<4

<OR=10 mcg/L

EN

Note 1

See Note 2

For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ199 (This link is being provided for informational/educational purposes only.)

Note 2

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the



Printed from Health Gorilla Secure Clinical Network. Copyright © 2025 Health Gorilla Inc. https://www.healthgorilla.com

UL

UL

Z4M

PATIENT INFORMATION:

## Joel Corcoran

Phone (H): (833) 753-1851 11/30/1980 DOB: Gender: Male Age: 44 Patient ID: 53573860

STATUS: Final

Quest

01/21/2025 08:57 PM **Time Reported:** 

UTC

01/21/2025 09:04 PM Received:

UTC

Accession SZ687587R

Number:

Source:

Lab Ref #: 915188 ORDERING PHYSICIAN:

## Joshua A Emdur,

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test	İr	n Range	Out Of Range	Reference Range	Lab
	FDA. This assay has been validate	ed pursuant to	the CLIA		
	regulations and is used for clini	ical purposes.			

#### ABO GROUP AND RH TYPE Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC **ABO GROUP**

**RH TYPE** RH(D) NEGATIVE

educational purposes only.)

For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ111 (This link is being provided for informational/

#### Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC MAGNESIUM, RBC

MAGNESIUM, RBC 4.0-6.4 mg/dL 73F 5.6

(Note)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

MDF med fusion 2501 South State Highway 121, Suite 1100 Lewisville TX 75067 972-966-7300

Ithiel James L. Frame, MD, PhD

#### LIPOPROTEIN FRACTIONATION ION MOBILITY Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05: 56 PM UTC

#### **LDL PARTICLE NUMBER** <1138 nmol/L 1652 H

Relative Risk: Optimal <1138; Moderate 1138-1409; High

>1409. Male and Female Reference Range: 1016 to 2185 nmol/L.

LDL SMALL <142 nmol/L Z4M

Relative Risk: Optimal <142; Moderate 142-219; High >219. Male Reference Range: 123 to 441 nmol/L; Female Reference Range: 115 to 386 nmol/L.

Z4M <215 nmol/L LDL MEDIUM 287 H Relative Risk: Optimal <215; Moderate 215-301; High >301.

Male Reference Range: 167 to 485 nmol/L; Female Reference Range: 121 to 397 nmol/L.

**HDL LARGE** >6729 nmol/L Z4M 3516 L

Relative Risk: Optimal >6729; Moderate 6729-5353; High <5353. Male Reference Range: 4334 to 10815 nmol/L; Female

Reference Range: 5038 to 17886 nmol/L.

**LDL PATTERN** Z4M A Pattern



Printed from Health Gorilla Secure Clinical Network. Copyright © 2025 Health Gorilla Inc. https://www.healthgorilla.com

Z4M

PATIENT INFORMATION:

## Joel Corcoran

Phone (H): (833) 753-1851 DOB: 11/30/1980 Gender: Male Age: 44 Patient ID: 53573860

#### STATUS: Final

Source: Quest

Time Reported: 01/21/2025 08:57 PM

UTC

**Received:** 01/21/2025 09:04 PM

UTC

Accession SZ687587R

Number:

**Lab Ref #:** 915188

ORDERING PHYSICIAN:

## Joshua A Emdur,

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test	est		ln	In Range (		Out Of Range		Reference Range	Lab	
	Relative Risk:	Optimal	Pattern	A;	High	Pattern	В.	Reference		

Range: Pattern A.

LDL PEAK SIZE 209.7 L >222.9 Angstrom

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Relative Risk: Optimal >222.9; Moderate 222.9-217.4; High <217.4. Male and Female Reference Range: 216 to 234.3 Angstrom. Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on an adult U.S. reference population plus two large cohort study populations. Association between lipoprotein subfractions and cardiovascular events is based on Musunuru et al. ATVB.2009;29:1975. For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ134 (This link is being provided for informational/educational purposes only.)

CARDIO IQ(R) LIPID PANEL	Collected: 01/13/2025 05:55 PM UTC	Received: 01/13/2025 05:56 PM UTC	
CHOLESTEROL, TOTAL	194	<200 mg/dL	Z4M
HDL CHOLESTEROL	47	>39 mg/dL	Z4M
TRIGLYCERIDES	111	<150 mg/dL	Z4M
LDL-CHOLESTEROL		<b>125 H</b> <100 mg/dL (calc)	Z4M

Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with >= 2 CHD risk factors.

LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing

better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19):

2061-2068 (http://education.QuestDiagnostics.com/fag/FAQ164)

LDL-C is now calculated using the Martin-Hopkins

calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the

estimation of LDL-C.
Martin SS et al. JAMA. 2013;310(19): 2061-2068

(http://education.QuestDiagnostics.com/faq/FAQ164)

CHOL/HDLC RATIO 4.1

147 H <130 mg/dL (calc)

<5.0 calc

Z4M Z4M

NON HDL CHOLESTEROL

For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.

For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL



Printed from Health Gorilla Secure Clinical Network. Copyright © 2025 Health Gorilla Inc. https://www.healthgorilla.com

## Joel Corcoran

Phone (H): (833) 753-1851 DOB: 11/30/1980 Gender: Male Age: 44 Patient ID: 53573860 STATUS: Final

Source: Quest

Time Reported: 01/21/2025 08:57 PM

UTC

**Received:** 01/21/2025 09:04 PM

UTC

Accession SZ687587R

Number:

**Lab Ref #:** 915188

ORDERING PHYSICIAN:

# Joshua A Emdur, D.O.

600 Congress Avenue

Floor 14

Austin, TX, 78701

Test In Range Out Of Range Reference Range Lab

(LDL-C of <70 mg/dL) is considered a therapeutic option.

Enhanced PDF Report SZ687587R-1 Collected: 01/13/2025 05:55 PM UTC Received: 01/13/2025 05:56 PM UTC

Enhanced PDF Report SZ687587R- Enhanced PDF Report SZ687587R-1.pdf [See Appendix 1 for details]

UL Quest Diagnostics-Sacramento - Northgate. Dir: Lorne L Holland 3714 Northgate Blvd, Sacramento, CA 95834-1617 ΕN Quest Diagnostics-West Hills. Dir: Thomas J McDonald 8401 Fallbrook Ave, West Hills, CA 91304-3226 ΕZ Quest Diagnostics/Nichols SJC-San Juan Capistrano,.. Dir: Irina Maramica MD, PhD, MBA 33608 Ortega Hwy, San Juan Capistrano, CA 92675-2042 Z3E MedFusion-MedFusion. Dir: Ithiel James L Frame MD, PhD 2501 South State Highway 121, Suite 1100, Lewisville, TX 75067-8188 Z4M Cleveland HeartLab Inc.-Cleveland HeartLab Inc.. Dir: Sami Albeiroti PhD, DABCC

Range Flags Legend: L - Below low normal; H - Above high normal; A - Abnormal;

6701 Carnegie Ave, Suite 500, Cleveland, OH 44103-4623



Printed from Health Gorilla Secure Clinical Network. Copyright © 2025 Health Gorilla Inc. https://www.healthgorilla.com





Patient Information	Specimen Information	Client Information
CORCORAN, JOEL  DOB: 11/30/1980 AGE: 44  Gender: M Fasting: Y  Phone: 833.753.1851  Patient ID: 53573860  Health ID: 8573036010014334	Specimen:         SZ687587R           Requisition:         0069519           Lab Ref #:         915188           Collected:         01/13/2025 / 09:55 PST           Received:         01/13/2025 / 21:34 PST           Reported:         01/21/2025 / 12:57 PST	Client #: 73917267 MAIL992 EMDUR, JOSHUA FUNCTION HEALTH INC 600 CONGRESS AVE FL 14 AUSTIN, TX 78701-3263

IRON, TIBC AND FERRITIN PANEL IRON AND TOTAL IRON BINDING CAPACITY IRON, TOTAL IRON BINDING CAPACITY % SATURATION FERRITIN LIPOPROTEIN (a)	141 284 182 <10	<b>50 H</b> Verified by r  Reference R	50-180 mcg/dL 250-425 mcg/dL (calc) 20-48 % (calc) 38-380 ng/mL nmol/L epeat analysis.	UL UL EN
IRON, TOTAL IRON BINDING CAPACITY  * SATURATION FERRITIN	284 182	Verified by r	250-425 mcg/dL (calc) 20-48 % (calc) 38-380 ng/mL nmol/L	
% <b>SATURATION</b> FERRITIN	182	Verified by r	20-48 % (calc) 38-380 ng/mL nmol/L	
FERRITIN		Verified by r	38-380 ng/mL nmol/L	
			nmol/L	
LIPOPROTEIN (a)	<10			EN
			epeat analysis.	
		Reference R		
		11020201100 11	ange <75	
		Risk:		
		Optimal	<75	
		Moderate	75-125	
		High	>125	
		cut points	lar event risk category (optimal, moderate, high) n Tsimika S. JACC -711.	
ALBUMIN, RANDOM URINE				$\mathtt{UL}$
W/O CREATININE				
ALBUMIN, URINE	0.4	Danas	mg/dL	
	Reference F			
The ADA defines abnormalitien excretion as follows:	es in albumin			
Albuminuria Category	Result (mg/	g creatinine)		
Normal to Mildly increased Moderately increased	<30 30-299			
Severely increased	> OR = 300			
The ADA recommends that at a specimens collected within a abnormal before considering within a diagnostic category	a 3-6 month po a patient to	eriod be		
HS CRP	0.6		mg/L	UL
Reference Range Optimal <1.0				
Jellinger PS et al. Endocr I	Pract.2017;23	(Suppl 2):1-87.		
For ages >17 Years:		(12.11)		
hs-CRP mg/L Risk According				
<1.0 Lower relative				
1.0-3.0 Average relativ				
3.1-10.0 Higher relative				
Consider retest exclude a benig				
in the baseline				





Patient Information	Specimen Informat	tion	Client Information	
CORCORAN, JOEL	_ *	7587R	Client #: 73917267	
CORCORII, SOLL	Collected: 01/13/	/2025 / 09:55 PST	EMDUR, JOSHUA	
DOB: 11/30/1980 AGE: 44	Received: 01/13/	/2025 / 21:34 PST		
Gender: M Fasting: Y	Reported: 01/21/	/2025 / 12:57 PST		
Patient ID: 53573860	1			
Health ID: 8573036010014334				
	T D	0 05 Domes	Defenses Dense	Lab
Test Name to infecti	<b>In Range</b> on or inflammation	Out Of Range	Reference Range	Lab
>10.0 Persistent	elevation, upon rociated with infec	retesting,		
Pearson TA, Mensah GA, of inflammation and car application to clinical A statement for health Centers for Disease Con American Heart Associat	diovascular diseas and public health are professionals atrol and Preventio	se: n practice: from the on and the		
499-511. APOLIPOPROTEIN B		101 н	mg/dL	EN
		Reference Ra	_	
		Dial Cata		
		Risk Categor Optimal	y: <90	
		Moderate	90-119	
		High	> or = 120	
COMPREHENSIVE METABOLIC		cut points ( are based on Association TA et al. J 9: 129-169 a	ar event risk category optimal, moderate, high) National Lipid recommendations-Jacobson of Clin Lipid. 2015; nd Jellinger PS et al 2017;23(Suppl 2):1-87.	UL
PANEL GLUCOSE	95		65-99 mg/dL	
0100001	75		03 99 mg/ db	
		Fa	sting reference interval	
UREA NITROGEN (BUN)	15		7-25 mg/dL	
CREATININE	1.11		0.60-1.29 mg/dL	
EGFR	84		> OR = 60  mL/min/1.73m2	
BUN/CREATININE RATIO	SEE NOTE:	mtod: DIM and C	6-22 (calc)	
	referenc		reatinine are within	
CODILINA	120		125 146	
SODIUM POTASSIUM	138 4.3		135-146 mmol/L 3.5-5.3 mmol/L	
CHLORIDE	104		98-110 mmol/L	
CARBON DIOXIDE	26		20-32 mmol/L	
CALCIUM	9.2		8.6-10.3 mg/dL	
PROTEIN, TOTAL	6.8		6.1-8.1 g/dL	
ALBUMIN	4.6		3.6-5.1 g/dL	
GLOBULIN	2.2		1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	2.1		1.0-2.5 (calc)	
BILIRUBIN, TOTAL	1.1		0.2-1.2  mg/dL	
ALKALINE PHOSPHATASE	50		36-130 U/L	
AST	22		10-40 U/L	
ALT	29		9-46 U/L	
HEMOGLOBIN Alc  For the purpose of scre	5.3	6	<5.7 % of total Hgb	$\mathtt{UL}$

For the purpose of screening for the presence of diabetes:





Patient Information	Specimen Information	Client Information	
CORCORAN, JOEL	Specimen: SZ687587R Collected: 01/13/2025 / 09:55 PST	Client #: 73917267 EMDUR, JOSHUA	
DOB: 11/30/1980 AGE: 44  Gender: M Fasting: Y  Patient ID: 53573860  Health ID: 8573036010014334	Received: 01/13/2025 / 21:34 PST Reported: 01/21/2025 / 12:57 PST		

Test Name In Range Out Of Range Reference Range Lab

> or =6.5% Consistent with diabetes

This assay result is consistent with a decreased risk of diabetes.

Currently, no consensus exists regarding use of hemoglobin Alc for diagnosis of diabetes in children.

According to American Diabetes Association (ADA) guidelines, hemoglobin A1c <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA).

URIC ACID	5.5	4.0-8.0  mg/dL	UL
Therapeutic target for gout p	patients: <6.0 mg/dL		
TSH	0.93	0.40-4.50 mIU/L	UL
T4, FREE	1.3	0.8-1.8 ng/dL	UL
T3, FREE	3.9	2.3-4.2 pg/mL	UL
CBC (INCLUDES DIFF/PLT)	3.9	2.5 1.2 pg/	UL
WHITE BLOOD CELL COUNT	5.2	3.8-10.8 Thousand/uL	01
RED BLOOD CELL COUNT	5.01	4.20-5.80 Million/uL	
HEMOGLOBIN	16.1	13.2-17.1 q/dL	
HEMATOCRIT	47.8	38.5-50.0 %	
MCV	95.4	80.0-100.0 fL	
MCH	32.1	27.0-33.0 pg	
MCHC	33.7	32.0-36.0 g/dL	
For adults, a slight decrease	e in the calculated MCHC	5, 11, 11, 11, 11, 11, 11, 11, 11, 11, 1	
value (in the range of 30 to			
not clinically significant;	however, it should be		
interpreted with caution in	correlation with other		
red cell parameters and the	patient's clinical		
condition.			
RDW	11.9	11.0-15.0 %	
PLATELET COUNT	232	140-400 Thousand/uL	
MPV	10.1	7.5-12.5 fL	
ABSOLUTE NEUTROPHILS	2808	1500-7800 cells/uL	
ABSOLUTE LYMPHOCYTES	1695	850-3900 cells/uL	
ABSOLUTE MONOCYTES	582	200-950 cells/uL	
ABSOLUTE EOSINOPHILS	62	15-500 cells/uL	
ABSOLUTE BASOPHILS	52	0-200 cells/uL	
NEUTROPHILS	54	96	
LYMPHOCYTES	32.6	96	
MONOCYTES	11.2	8	
EOSINOPHILS	1.2	8	
BASOPHILS	1.0	%	
URINALYSIS, COMPLETE			$\mathtt{UL}$
COLOR	YELLOW	YELLOW	
APPEARANCE	CLEAR	CLEAR	

SPECIMEN: SZ687587R

SPECIFIC GRAVITY

PH

1.001-1.035

5.0-8.0

1.013

6.0





Patient Information	Specimen Information	Client Information	
CORCORAN, JOEL	Specimen: SZ687587R Collected: 01/13/2025 / 09:55 PST	Client #: 73917267 EMDUR, JOSHUA	
DOB: 11/30/1980 AGE: 44  Gender: M Fasting: Y  Patient ID: 53573860  Health ID: 8573036010014334	Received: 01/13/2025 / 21:34 PST Reported: 01/21/2025 / 12:57 PST		

Test Name	In Range	Out Of Range	Reference Ra	ange Lab
GLUCOSE	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
KETONES	NEGATIVE		NEGATIVE	
OCCULT BLOOD	NEGATIVE		NEGATIVE	
PROTEIN	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
LEUKOCYTE ESTERASE	NEGATIVE		NEGATIVE	
WBC	NONE SEEN		< OR = 5 / HP	PF
RBC	NONE SEEN		< OR = 2 / HP	PF
SQUAMOUS EPITHELIAL CELLS	NONE SEEN		< OR = 5 / HP	PF
BACTERIA	NONE SEEN		NONE SEEN /H	IPF
HYALINE CAST	NONE SEEN		NONE SEEN /L	.PF
This urine was analyzed for	the presence of	of WBC,		
RBC, bacteria, casts, and ot	her formed ele	ements.		
Only those elements seen wer	e reported.			

CORTISOL, TOTAL, LC/MS

9.9

mcg/dL

EZ

ΕN

ΕN

UL

Adult Reference Ranges for Cortisol, Total:

8-10 AM 4.6-20.6 mcg/dL 4-6 PM 1.8-13.6 mcg/dL

Cortisol Response to ACTH

Peak >20.0 mcg/dL

Peak >16.0 mcg/dL after IM injection

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

INSULIN 5.8

uIU/mL

Reference Range < or = 18.4

Risk:

Optimal < or = 18.4

Moderate NA High >18.4

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Insulin Reference Interval studies performed at Quest Diagnostics

in 2022.

MERCURY, BLOOD <4 <0R=10 mcg/L

See Endnote 1

ABO GROUP AND RH TYPE

ABO GROUP

RH TYPE RH(D) NEGATIVE

For additional information, please refer to





Patient Information	Specimen Information	Client Information
CORCORAN, JOEL	Specimen: SZ687587R Collected: 01/13/2025 / 09:55 PST	Client #: 73917267 EMDUR, JOSHUA
DOB: 11/30/1980 AGE: 44 Gender: M Fasting: Y Patient ID: 53573860 Health ID: 8573036010014334	Received: 01/13/2025 / 21:34 PST Reported: 01/21/2025 / 12:57 PST	

Test Name In Range Out Of Range Reference Range Lab http://education.QuestDiagnostics.com/faq/FAQ111 (This link is being provided for informational/ educational purposes only.)

MAGNESIUM, RBC 5.6 4.0-6.4 mg/dL Z3E (Note)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

MDF med fusion 2501 South State Highway 121,Suite 1100 Lewisville TX 75067 972-966-7300 Ithiel James L. Frame, MD, PhD

#### **Endnote 1**

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.





Patient Information	Specimen Information	Client Information
CORCORAN, JOEL	Specimen: SZ687587R Collected: 01/13/2025 / 09:55 PST	Client #: 73917267 EMDUR, JOSHUA
DOB: 11/30/1980 AGE: 44  Gender: M Fasting: Y  Patient ID: 53573860  Health ID: 8573036010014334	Received: 01/13/2025 / 21:34 PST Reported: 01/21/2025 / 12:57 PST	

#### Endocrinology

Endocrinology				
Test Name		Result	Reference Range	Lab
VITAMIN D,25-OH,TOTAL,IA		41	30-100 ng/mL	UL
Vitamin D Status	25-OH Vitamin	D:		
Deficiency: Insufficiency: Optimal: For 25-OH Vitamin D testing on p QuestAssureD(TM) 25-OH VIT D		nL nL tation and patients for whom q	uantitation of D2 and D3 fractions is i 38 (patients >2yrs).	required, the
For additional information, please repurposes only.)	efer to http://education.Qu	estDiagnostics.com/faq/FAQ1	99 (This link is being provided for info	ormational/ educational
Physician Comments:				







<b>Patient Information</b>	Specimen Information	Client Information	
CORCORAN, JOEL	Specimen: SZ687587R Collected: 01/13/2025 / 09:55 PST	Client #: 73917267 EMDUR, JOSHUA	
DOB: 11/30/1980 AGE: 44  Gender: M Fasting: Y  Patient ID: 53573860  Health ID: 8573036010014334	Received: 01/13/2025 / 21:34 PST Reported: 01/21/2025 / 12:57 PST		

			Cardio I	$\mathbf{Q}$ ®			
	Cu	irrent	Risk	/Reference Int	erval		Historical
Test Name		t & Risk	Optimal	Moderate	High	Units	Result & Risk
	Optimal	Non-Optimal					
LIPID PANEL							
CHOLESTEROL, TOTAL	194		<200	N/A	>=200	mg/dL	
HDL CHOLESTEROL	47		>=40	N/A	<40	mg/dL	
TRIGLYCERIDES	111		<150	150-199	>=200	mg/dL	
LDL-CHOLESTEROL		125	<100	100-129	>129	mg/dL	
						(calc)	
CHOL/HDLC RATIO		4.1	<=3.5	3.6-5.0	>5.0	calc	
NON-HDL CHOLESTEROL		147	<130	130-189	>=190	mg/dL	
——————————————————————————————————————				130-109	<i>&gt;</i> =190	(calc)	
LIPOPROTEIN FRACTIO	NATION, IC	ON MOBILIT					
LDL PARTICLE NUMBER		1652	<1138	1138-1409	>1409	nmol/L	
LDL SMALL		427	<142	142-219	>219	nmol/L	
LDL MEDIUM		287	<215	215-301	>301	nmol/L	
HDL LARGE		3516	>6729	6729-5353	<5353	nmol/L	
LDL PATTERN		В	А	N/A	В	Pattern	
LDL PEAK SIZE		209.7	>222.9	222.9-217.4	<217.4	Angstrom	

For details on reference ranges please refer to the reference range/comment section of the report.

Medical Information For Healthcare Providers: If you have questions about any of the tests in our Cardio IQ offering, please call Client Services at our Quest Diagnostics-Cleveland HeartLab Cardiometabolic Center of Excellence. They can be reached at 866.358.9828, option 1 to arrange a consult with our clinical education team.





<b>Patient Information</b>	Specimen Information	Client Information
CORCORAN, JOEL	Specimen: SZ687587R Collected: 01/13/2025 / 09:55 PST	Client #: 73917267 EMDUR, JOSHUA
DOB: 11/30/1980 AGE: 44 Gender: M Fasting: Y Patient ID: 53573860 Health ID: 8573036010014334	Received: 01/13/2025 / 21:34 PST Reported: 01/21/2025 / 12:57 PST	

Reference Range/Comments						
Analyte Name	In Range	Out Range	Reference Range	Lab		
HDL LARGE		3516	>6729 nmol/L	Z4M		
Relative Risk: Optimal >6729; Moderate 6729-5353;	High <5353. Male Re	ference Range: 4334	to 10815 nmol/L; Female Reference Range: 5038 to 1	7886 nmol/L.		
LDL MEDIUM		287	<215 nmol/L	Z4M		
Relative Risk: Optimal <215; Moderate 215-301; Hig	h >301. Male Referen	ce Range: 167 to 485	nmol/L; Female Reference Range: 121 to 397 nmol/L.			
LDL PARTICLE NUMBER		1652	<1138 nmol/L	Z4M		
Relative Risk: Optimal <1138; Moderate 1138-1409;	High >1409. Male and	d Female Reference F	Range: 1016 to 2185 nmol/L.			
LDL PATTERN		В	A Pattern	Z4M		
Relative Risk: Optimal Pattern A; High Pattern B. Re	ference Range: Patte	rn A.				
LDL PEAK SIZE		209.7	>222.9 Angstrom	Z4M		
	rdiovascular events is	based on Musunuru	S. reference population plus two large cohort study poper al. ATVB.2009;29:1975. For additional information, pational purposes only.)  <142 nmol/L			
Relative Risk: Optimal <142; Moderate 142-219; High >219. Male Reference Range: 123 to 441 nmol/L; Female Reference Range: 115 to 386 nmol/L.						
LDL-CHOLESTEROL		125	<100 mg/dL (calc)	Z4M		
	el method providing be	etter accuracy than the	c patients with >= 2 CHD risk factors. LDL-C is now call Friedewald equation in the estimation of LDL-C. Marti			
NON HDL CHOLESTEROL		147	<130 mg/dL (calc)	Z4M		
For patients with diabetes plus 1 major ASCVD risk f	actor, treating to a no	n-HDL-C goal of <100	mg/dL (LDL-C of <70 mg/dL) is considered a theraped	utic option.		
CHOL/HDLC RATIO	4.1		<5.0 calc	Z4M		
CHOLESTEROL, TOTAL	194		<200 mg/dL	Z4M		
HDL CHOLESTEROL	47		>39 mg/dL	Z4M		
TRIGLYCERIDES	111		<150 mg/dL	Z4M		

#### **PERFORMING SITE:**

- QUEST DIAGNOSTICS-WEST HILLS, 8401 FALLBROOK AVENUE, WEST HILLS, CA 91304-3226 Laboratory Director: THOMAS MCDONALD, MD, CLIA: 05D0642827
- QUEST DIAGNOSTICS: WEST HILLS, 8401 FALLEROUK AVENUE, WEST HILLS, CA 91504-3220 Laboratory Director: HOMAS MICDONALD, MID, CLIA: 05D0642827
  QUEST DIAGNOSTICS NICHOLS SIC, 33608 ORTEGA HWY, SAN JUAN CAPISTRANO, CA 92675-2042 Laboratory Director: IRINA MARAMICA, MD, PHD, MBA, CLIA: 05D0643352
  QUEST DIAGNOSTICS SACRAMENTO, 3714 NORTHGATE BLVD, SACRAMENTO, CA 95834-1617 Laboratory Director: LORNE L. HOLLAND, MD, CLIA: 05D0644209
  MEDFUSION, 2501 SOUTH STATE HIGHWAY 121 SUITE 1100, LEWISVILLE, TX 75067-8188 Laboratory Director: ITHIEL J FRAME, MD, PHD, CLIA: 45D2004217
  CLEVELAND HEARTLAB INC, 6701 CARNEGIE AVENUE SUITE 500, CLEVELAND, OH 44103-4623 Laboratory Director: SAMI ALBEIROTI, PHD, DABCC, CLIA: 36D1032987 ΕZ

- UL Z3E Z4M